Get the Stockscreener App
1,077.19
0.35%
-3.81
After Hours:
1077.66
0.47
+0.04%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,077.19, with a volume of 2.19M.
It is down -0.35% in the last 24 hours and up +4.83% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,081.00
Open:
$1083
24h Volume:
2.19M
Relative Volume:
0.64
Market Cap:
$964.11B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
53.27
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+1.24%
1M Performance:
+4.83%
6M Performance:
+35.84%
1Y Performance:
+35.07%
1-Day Range:
$1,069.09
$1,090.22
1-Week Range:
$1,058.00
$1,133.95
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,077.19 | 967.52B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
213.65 | 505.28B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
220.75 | 388.90B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.61 | 272.12B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.26 | 271.01B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - MarketBeat
French Government Shoots Down Rumors Eli Lilly (LLY) Is Planning to Acquire Biotech Firm Abivax - TipRanks
Eli Lilly CFO: Weight-loss pill could have 20% global penetration - Yahoo Finance UK
A 10% Owner Of Structure Therapeutics Shed Shares - The Motley Fool
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms - TechStock²
JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher - Genetic Engineering and Biotechnology News
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz
Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds - Benzinga
The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh - Yahoo Finance Singapore
Nvidia Drives 70% Drug‑Discovery Cost Crash; Lilly Bets $1BEli Lilly and Co (NYSE:LLY), NVIDIA (NASDAQ:NVDA) - Benzinga
Lilly and NVIDIA: a $1bn leap for drug discovery - European Medical Journal
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Yahoo Finance
Eli Lilly (LLY) Targets Q2 2026 FDA Approval for Obesity Pill - GuruFocus
What to Expect From Eli Lilly’s Q4 2025 Earnings Report - Barchart.com
Eli Lilly CFO says obesity pill on track for FDA nod in Q2 - Seeking Alpha
Eli Lilly and Nividia Commit $1B Over 5 Years for AI-Driven Drug Discovery Lab - AI Insider
NVIDIA to Invest US$1 Billion in an AI Drug Laboratory with Eli Lilly - Eudaimonia and Co
Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com
Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup - Chartmill
Eli Lilly Stock Rises on $1 Billion AI Bet With Nvidia - GuruFocus
NVIDIA & Eli Lilly: AI Lab a New Dawn for Drug Manufacturing - Manufacturing Digital
NVIDIA, Lilly launch $1B AI Lab to transform drug discovery - Qazinform
Eli Lilly and NVIDIA invest in AI-driven pharmaceutical innovation - Digital Watch Observatory
Nvidia (NVDA) Stock; Gains Slightly on $1B AI Co-Innovation Lab with Eli Lilly - CoinCentral
NVIDIA, Eli Lilly Launch Physical AI Institute - 조선일보
Nvidia and Eli Lilly launch joint AI lab to advance drug discovery and manufacturing - digitimes
Nvidia-Lilly $1B AI Lab To Transform Drug Discovery - Electronics For You BUSINESS
First-of-Its-Kind AI Drug Discovery Lab: NVIDIA, Eli Lilly Announce $1B Investment at J.P. Morgan Healthcare - geneonline.com
Nvidia, Eli Lilly plan $1 billion AI laboratory to accelerate drug research - StoryBoard 18
Risk Recap: Can Eli Lilly and Company weather a recessionWeekly Market Report & Daily Momentum Trading Reports - baoquankhu1.vn
AI healthcare enters a golden era of development! NVIDIA and Eli Lilly and Co invest in AI-driven drug discovery, while OpenAI acquires healthcare startup Torch. - 富途牛牛
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.
NVIDIA and Eli Lilly and Co are investing in AI-driven pharmaceuticals, with the potential to integrate robotics technology in the future. A new growth pole in the healthcare industry is gradually taking shape. - 富途牛牛
Nvidia, Lilly to invest up to $1B in new AI medical research lab - SiliconANGLE
AI-driven drug discovery gets $1 billion boost from Nvidia, Lilly - WISH-TV
JPM26, Day 1: Lilly, Nvidia expand AI team-up; Takeda R&D head talks lack of deal announcements - Fierce Biotech
NVIDIA And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI - Pulse 2.0
Nvidia and Eli Lilly to open joint AI lab focused on drug development in South San Francisco - The Business Journals
Lilly will have supply of new weight loss pill for many countries, exec says - Reuters
Nvidia, US firm Eli Lilly to launch $1b AI co-innovation lab - Tech in Asia
Top Stock Reports for Microsoft, Eli Lilly & Lam Research - Yahoo Finance Singapore
Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab - Reuters
France denies contact with Eli Lilly over reported $17.5 bln Abivax deal - Reuters
Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly - Bloomberg.com
NVIDIA and Lilly Announce Co-Innovation AI Lab for Drug Discovery - HPCwire
Nvidia partners with Lilly to launch $1B AI drug discovery lab - TechTarget
Eli Lilly Launches Multi-Billion Dollar Strategic Expansion - AD HOC NEWS
Nvidia, Eli Lilly commit $1B to AI drug discovery lab - theregister.com
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Reinvent Drug Discovery - HIT Consultant
Eli Lilly (LLY) Prepares for Global Launch of Weight Loss Pill - GuruFocus
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):